Hansoh actively implements the internationalization strategy and has been committed itself to human being’s health with its professional expertise, through sales of internationally certified APIs and finished-dose pharmaceutical products to the U.S. and other countries, and international multi-center clinical trials for innovative drugs.
Market Internationalization
Multiple finished-dose pharmaceutical products and APIs are sold to the global market.
R&D Internationalization
Global multi-center clinical trials are under way simultaneously in the U.S. and China for HS-10296, a Category 1.1 innovative oncology drug, amid efforts for global expansion of innovative drugs.